全文获取类型
收费全文 | 342篇 |
免费 | 12篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 7篇 |
妇产科学 | 5篇 |
基础医学 | 4篇 |
口腔科学 | 15篇 |
临床医学 | 12篇 |
内科学 | 43篇 |
皮肤病学 | 2篇 |
神经病学 | 13篇 |
特种医学 | 10篇 |
外科学 | 45篇 |
预防医学 | 1篇 |
药学 | 15篇 |
肿瘤学 | 180篇 |
出版年
2023年 | 3篇 |
2022年 | 6篇 |
2021年 | 8篇 |
2020年 | 5篇 |
2019年 | 5篇 |
2018年 | 11篇 |
2017年 | 11篇 |
2016年 | 7篇 |
2015年 | 10篇 |
2014年 | 11篇 |
2013年 | 15篇 |
2012年 | 25篇 |
2011年 | 22篇 |
2010年 | 5篇 |
2009年 | 13篇 |
2008年 | 21篇 |
2007年 | 12篇 |
2006年 | 14篇 |
2005年 | 9篇 |
2004年 | 6篇 |
2003年 | 14篇 |
2002年 | 10篇 |
2001年 | 15篇 |
2000年 | 15篇 |
1999年 | 17篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 5篇 |
1995年 | 5篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 7篇 |
1987年 | 4篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 4篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1975年 | 2篇 |
1972年 | 2篇 |
1969年 | 3篇 |
1968年 | 1篇 |
1967年 | 2篇 |
1965年 | 1篇 |
排序方式: 共有354条查询结果,搜索用时 15 毫秒
1.
2.
3.
Shinichiro Takahashi Taira Kinoshita Masaru Konishi Toshio Nakagouri Kazuto Inoue Masato Ono Masanori Sugitou Atsushi Ohtsu Narikazu Boku Shigeaki Yoshida 《Gastric cancer》2001,4(4):192-197
Background. The prognosis of scirrhous gastric cancer remains poor when it is treated with surgical resection alone or chemotherapy alone.
A phase II study of sequential high-dose methotrexate and fluorouracil, combined with doxorubicin, as a neoadjuvant chemotherapy
was conducted in an attempt to evaluate the efficacy of this regimen in improving the survival of patients with scirrhous
gastric cancer.
Methods. Patients were eligible if they had potentially resectable scirrhous gastric cancer with adequate organ functions and no prior
treatment. The treatment schedule consisted of methotrexate (1 g/m2, day 1) fluorouracil (1.5 g/m2, day 1), leucovorin (15 mg/m2, days 2–4), and doxorubicin (30 mg/m2, day 15), repeated at a 28-day interval, and followed by radical surgery.
Results. A total of 20 eligible patients were registered. Objective responses in the neoadjuvant chemotherapy segment were observed
in 3 of the 20 (15%) patients. No complete remission was observed. The neoadjuvant chemotherapy was associated with grade
3 or 4 neutropenia in 14 of the 20 (70%) patients. The median time from the initial therapy to the operative day was 82 days.
Thirteen of the 20 (65%) patients underwent curative resection. No treatment-related deaths occurred. However, the 2-year
survival rate in this treatment program (25%) did not show any superiority over that in historical controls.
Conclusions. Sequential high-dose methotrexate and fluorouracil, combined, with doxorubicin, as a neoadjuvant chemotherapy for scirrhous
gastric cancer did not improve the survival rate in spite of improving the curative resection rate.
Received: August 2, 2001 / Accepted: September 27, 2001 相似文献
4.
Dr. Hideho Takada M.D. Kazuhiko Yoshioka M.D. Tsunehiko Boku M.D. Ryo Yoshida M.D. Kuniyuki Nakagawa M.D. Tadashi Matsuda M.D. Koshiro Hioki M.D. 《Diseases of the colon and rectum》1995,38(12):1325-1326
An easy and simple method for constructing a urinary diversion in patients undergoing pelvic exenteration for advanced rectal cancer is described. This procedure features double-barreled colostomy with a segment of the sigmoid colon 8 to 10 cm distal to the stoma as a urinary conduit.Read at the meeting of the Japanese Research Society for Cancer of the Colon and Rectum, Tokyo, Japan, July 29, 1994. 相似文献
5.
Hiroshi Hoshijima Koichi Maruyama Takahiro Mihara Aiji Sato Boku Toshiya Shiga Hiroshi Nagasaka 《Medicine》2020,99(48)
Background:It is presently unclear whether the hemodynamic response to intubation is less marked with indirect laryngoscopy using the GlideScope (GlideScope) than with direct laryngoscopy using the Macintosh laryngoscope. Thus, the aim of this study was to determine whether using the GlideScope lowers the hemodynamic response to tracheal intubation more than using the Macintosh laryngoscope.Methods:We performed a comprehensive literature search of electronic databases for clinical trials comparing hemodynamic response to tracheal intubation. The primary aim was to determine whether the heart rate (HR) and mean blood pressure (MBP) 60 s after tracheal intubation with the GlideScope were lower than after intubation with the Macintosh laryngoscope. We expressed pooled differences in HR and MBP between the devices as the weighted mean difference with 95% confidence interval and also performed trial sequential analysis (TSA). Second, we examined whether use of the GlideScope resulted in lower post-intubation hemodynamic responses at 120, 180, and 300 s compared with use of the Macintosh laryngoscope. For sensitivity analysis, we used a multivariate random effects model that accounted for within-study correlation of the longitudinal data.Results:The literature search identified 13 articles. HR and MBP at 60 seconds post-intubation was not significantly lower with the GlideScope than with the Macintosh (HR vs MBP: weighted mean difference = 0.22 vs 2.56; 95% confidence interval −3.43 to 3.88 vs −0.82 to 5.93; P = .90 vs 0.14; I2 = 77% vs 63%: Cochran Q, 52.7 vs 27.2). Use of the GlideScope was not associated with a significantly lower HR or MBP at 120, 180, or 300 s post-intubation. TSA indicated that the total sample size was over the futility boundary for HR and MBP. Sensitivity analysis indicated no significant association between use of the GlideScope and a lower HR or MBP at any measurement point.Conclusions:Compared with the Macintosh laryngoscope, the GlideScope did not lower the hemodynamic response after tracheal intubation. Sensitivity analysis results supported this finding, and the results of TSA suggest that the total sample size exceeded the TSA monitoring boundary for HR and MBP. 相似文献
6.
New endoscopic treatment for intramucosal gastric tumors using an insulated-tip diathermic knife 总被引:20,自引:0,他引:20
BACKGROUND AND STUDY AIMS: For one-piece resection the conventional technique of endoscopic mucosal resection (EMR) is limited to gastric mucosal tumors of 10 mm or less in size. In this retrospective study, we investigated the efficacy and complications associated with a new EMR method, using an insulated-tip diathermic knife (IT-EMR). PATIENTS AND METHODS: In a total of 41 patients gastric mucosal tumors were resected using IT-EMR. Results: One-piece resection rates were 82% (14/17) for lesions of 10 mm or less, 75% (12/16) for those between 11 and 20 mm, and 14% (1/7) for those of over 20 mm. Complication rates for severe bleeding and perforation were 22% and 5%, respectively. With a median follow-up period of 32 months, no recurrence was observed after these procedures. CONCLUSIONS: Compared with conventional EMR, this new method may have significant benefits, particularly regarding one-piece resection of lesions between 11 and 20 mm in size, and may also have a lower recurrence rate. 相似文献
7.
8.
Narikazu Boku 《International journal of clinical oncology / Japan Society of Clinical Oncology》2008,13(6):483-487
Until the 1990s, there were no chemotherapy regimens with old-generation anticancer agents showing a survival benefit over
5-fluorouracil (FU) alone, and standard chemotherapy for metastatic gastric cancer had not been established. In the late 1990s,
several new active agents were developed and some phase III trials with these agents were conducted; the new agent S-1 showed
noninferiority to 5-FU in these trials. S-1 plus cisplatin is the first doublet chemotherapy to have shown a survival benefit
over monotherapy with S-1. It has been demonstrated that capecitabine and oxaliplatin (OHP) can replace 5-FU and cisplatin
(CDDP), offering more convenient treatment options. Thus, combination chemotherapy with an oral fluoropyrimidine (S-1 or capecitabine)
and platinum (CDDP or OHP) has been recognized as standard chemotherapy for metastatic gastric cancer all over the world.
However, it can be said that none of these new combination chemotherapies have shown remarkable progress from 5-FU plus cisplatin
regimens. It is expected that triplet chemotherapy with a taxane; the use of molecular targeting agents; and the establishment
of treatment strategies including second line chemotherapy, will lead to remarkable progress in personalized medicine in the
near future. 相似文献
9.
Kei Muro Atsushi Ohtsu Narikazu Boku Takahiro Fujii Yasushi Oda Koichi Hosokawa Ikuro Koba Hisao Tajiri Shigeaki Yoshida Takashi Ogino 《International journal of clinical oncology / Japan Society of Clinical Oncology》1996,1(3):176-181
Two cases of advanced esophageal carcinoma complicated by fistula formation, treated with esophageal prostheses followed by
chemotherapy or concurrent chemoradiotherapy, are reported. Chemoradiotherapy may be indicated in esophageal carcinoma cases
with fistulas if an excellent antitumor response is expected. However, the indication for prosthesis insertion should be limited
due to the risk of perforation, which may be a lethal complication. 相似文献
10.
Miyamoto S Boku N Ohtsu A Yoshida S Ochiai A Okabe H Fukushima M 《International journal of oncology》2000,17(4):653-658
Many reports have demonstrated that thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) are biomarkers for the response and prognosis of patients treated with 5-fluorouracil (5-FU)-based chemotherapy. A newly developed orally administered drug, fluoropyrimidine (S-1), has been developed with clinical efficacy when combined with an inhibitor of DPD. In this study, the relationship between immunoreactivity to TS and DPD in biopsy specimens and the effects of chemotherapy was investigated in 41 patients treated with S-1 therapy for advanced gastric cancer. Response rates were 54% (13/24) in TS(+) and 53% (9/17) in TS(-) patients (p=0.938), and those of DPD(+) and (-) patients were 61% (11/18) and 48% (11/23) (p=0.397), respectively. The median survival time of all the subjects was 253 days. There was no significant difference in median survival time between TS(+) patients (284 days) and (-) patients (189 days: p=0.670). The 18 DPD(+) patients had median survival times slightly longer (338 days) than the 23 patients with DPD(-) (207 days: p=0.206). This study indicates that S-1 may be effective in the treatment of gastric cancer patients, regardless of intratumoral TS and DPD immunoreactivity status. Further studies are needed to confirm these results with larger numbers of patients. 相似文献